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Anaplastic large cell lymphoma (ALCL) represents a
rare and aggressive subtype of CD30-positive peripheral
T-cell lymphoma, which accounts for 5–10% of non-
Hodgkin lymphomas in adults and 10–30% in children1.
Anaplastic lymphoma kinase (ALK) fusions are present in
both solid and hematologic malignancies. More than 80%
of ALK-positive ALCLs are hallmarked by the fusion gene
nucleophosmin (NPM1)-ALK generated by the t(2;5)
chromosomal translocation, and 5% of non-small cell lung
cancer patients carry echinoderm microtubule-associated
protein-like 4 (EML4)-ALK fusion1. NPM1 is a nucleolar
phosphoprotein involved with chaperoning of proteins
and nucleic acids2. ALK is a receptor tyrosine kinase
belonging to the insulin receptor superfamily. NPM1-
ALK fusion protein p80 is derived from the fusion of the
N-terminal oligomerization domain of NPM1 (1–110 aa)
and the C-terminal tyrosine kinase domain of ALK
(1058–1620 aa)3. In these malignancies, the homo-
dimerization of NPM1-ALK leads the constitutive acti-
vation of a fusion kinase in a ligand-independent manner.
The persistently active tyrosine kinase NPM1-ALK trig-
gers multiple intracellular downstream signaling pathways
including AKT, ERK1/2, and STAT3, which results in
proliferation and survival of ALCL cells1.
Many ALK tyrosine kinase inhibitors have been devel-
oped, evaluated, and approved for clinical trials in
malignancies associated with ALK fusion genes. Clinical
resistance is a major problem associated with these ALK
inhibitors. One of the explored mechanisms responsible
for resistance to ALK inhibitors in these malignant cells is
through acquired secondary mutations in the kinase
domain4. Overall, current therapeutic approaches used for
the treatment of ALK-positive ALCLs has limited effec-
tiveness, resulting in a substantial percentage of cases with
poor outcomes, either failing to achieve remission or
relapsing within a short period. Hence, there is a need to
focus on developing novel and effective treatment stra-
tegies to overcome this clinical conundrum.
More than 500 protein kinases are present in the human
kinome and they play an essential role in cellular pro-
cesses such as cell proliferation, signaling, differentiation,
and apoptosis5. Dysregulation of these protein kinase
functions (genetic alterations including mutations or
fusion genes) is responsible for various pathological
conditions including cancer. Protein kinases depend on a
central molecular chaperone, heat shock protein 90
(HSP90) for their maturation and to protect against pro-
teasomal degradation. HSP90 is an ATPase-dependent
master chaperone that accounts for around 10% of the
proteome. It is important to note, the majority of mutated
kinase proteins involved with malignancies are main-
tained through HSP90 dependency, leading to “HSP90
addiction.” Exploitation of HSP90 by oncogenic kinases
for their stability and maturation makes HSP90 as a viable
molecular target6. Several HSP90 inhibitors bind to the
ATP binding site of HSP90 and promote degradation of
oncogenic protein kinases. Mutant fusion kinases such as
BCR-ABL and NPM1-ALK are known HSP90 client
proteins in hematologic malignancies7. Several preclinical
studies have been very supportive in considering HSP90
as a therapeutic target. However, many clinical trials using
HSP90 inhibitors have been halted due to toxicity asso-
ciated with the robust heat shock response8. An
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alternative approach to effectively target these HSP90-
dependent oncogenic kinases, while minimizing non-
specific toxicity could be disrupting the interaction
between HSP90 and its co-chaperones. HSP90 chaperone
machinery is complex, and along with HSP90, many co-
chaperones are involved in the process. Cyclin-dependent
kinase 37 (CDC37) is a specific co-chaperone recruiter for
a diverse group of protein kinases. HSP90-mediated
maturation of these oncogenic kinases strictly depends
on CDC379. Celastrol, a triterpene molecule extracted
from the Chinese herbal plant Tripterygium wilfordii
Hook F, blocks the interaction between HSP90 and
CDC37 and thereby triggers the degradation of its
dependent client protein kinases. Mechanistically, celas-
trol does not interfere with ATP binding to HSP90, but
inhibits the critical interaction and binding between the
N-terminal region of CDC37 (Arg167) and the middle
domain of HSP90 (Glu33)10.
In this study, we tested the fusion oncogene NPM1-
ALK dependency on co-chaperone CDC37 by disrupting
the interaction between HSP90 and CDC37, using celas-
trol as a therapeutic approach in ALCL cells. We have
utilized a total of six cell lines: NPM1-ALK endogenously
expressing human ALCL cell lines (SUDHL-1, Karpas-
299, SUP-M2, SR-786, and DEL), and our laboratory
generated ectopically overexpressing Ba/F3-FG-NPM1-
ALK, a murine cell line. In this report, we present
celastrol-mediated effects on apoptosis, proliferation,
oncogenic signaling, and CD30 (cluster of differentiation
30) expression in ALCL cells.
Earlier studies demonstrated NPM1-ALK as an HSP90
client protein by using the HSP90 ATPase inhibitor-
17AAG11. Several protein kinases are well characterized
for their dependency on CDC37 co-chaperoning, but very
limited studies are available for fusion kinases. In hema-
tologic malignancies, BCR-ABL was the first fusion kinase
identified to be dependent on CDC37 co-chaperone
interaction for its stability12. Our experiments confirmed
that endogenous NPM1-ALK fusion protein levels in
SUDHL-1, Karpas-299, SUP-M2, SR-786, and DEL cells
were diminished with celastrol treatment in a dose-
dependent manner (0.25–1.0 µM) after 24 h (Fig. 1a). In
similar lines, ectopically overexpressed NPM1-ALK was
also downregulated in Ba/F3 cell line. The decrease in
total NPM1-ALK resulted in a reduction of active phos-
phorylated NPM1-ALK (Fig. 1a). With the significant
decrease in protein levels of total NPM1-ALK and phos-
pho-NPM1-ALK, we further examined the influence of
these effects on relevant NPM1-ALK downstream sig-
naling in five NPM1-ALK expressing cell lines. AKT/
PI3K, MAPK/ERK, and STAT3 are well-studied survival
signaling pathways that are activated by NPM1-ALK in
CD30-positive ALCL cells13. Celastrol-mediated down-
regulation of NPM1-ALK phosphorylation inhibited
downstream signaling activators phosphorylated AKT,
ERK1/2, and STAT3 in a dose-dependent manner. There
was a minimal effect on total AKT, ERK1/2, STAT3
proteins, and β-actin levels were used as loading control
(Fig. 1b). Based on these experimental results, celastrol
downregulates fusion protein NPM1-ALK by blocking the
interaction between HSP90 and CDC37, which in turn
inhibits downstream survival signaling cascade AKT,
ERK1/2, and STAT3.
We then evaluated the ability of celastrol to induce
apoptosis in NPM1-ALK endogenously expressing
SUDHL-1, Karpas-299, SUP-M2, SR-786, DEL, and
ectopically expressing Ba/F3-FG-NPM1-ALK lymphoma
cell lines along with normal T cells. All selected ALCL cell
lines were treated with celastrol (0.1–1.0 µM) for 48 h,
and apoptosis was measured by flow cytometry using
FITC-annexin V and TO-PRO-3. All of the tested NPM1-
ALK fusion gene expressing cell lines were sensitive to
celastrol and showed induced apoptosis in a dose-
dependent manner compared to controls but no sig-
nificant effect on normal T cells (Fig. 2a). Overall, celas-
trol showed growth inhibitory effects on both endogenous
and ectopic NPM1-ALK expressing cell lines. PARP (poly
(ADP-ribose) polymerase) catalyzes poly(ADP-ribosyl)
ation of nuclear proteins involved in DNA transcription,
replication, and repair. During apoptosis, it is well known
that PARP is cleaved by specific caspases. Cancer cells are
associated with an imbalance between pro- and anti-
apoptotic genes14. Therefore, we examined PARP clea-
vage, activation of caspases, and differential regulation of
pro-apoptotic (BAX) and anti-apoptotic molecules (sur-
vivin, Bcl2, and c-Myc). Two cell lines, SUDHL-1 and
Karpas-299 were treated with 0.25–1.0 µM celastrol for
24 h. Celastrol treatment in these cell lines showed PARP
cleavage, downregulation of procaspases 8 and 9, upre-
gulation of pro-apoptotic protein BAX and down-
regulation of anti-apoptotic proteins survivin, Bcl2, and c-
Myc in a dose-dependent manner (Fig. 2b). All the eval-
uated proteins involved in apoptosis are activated by the
downstream signaling axis of NPM1-ALK13.
The chimera NPM1-ALK drives the proliferation of ALCL
cells. Therefore, we tested the effect of celastrol on the
proliferation of NPM1-ALK-positive cells using a standard
methylcellulose clonogenic assay. Karpas-299 and SUP-M2
cells were treated with 0, 0.5, and 1.0 µM celastrol for 24 h.
Cells were then washed, mixed with a MethoCult medium,
plated, and incubated for 8 days. The total number of
colonies were counted in each condition. There was a sig-
nificant reduction in the clonogenic potential of celastrol-
treated Karpas-299 and SUP-M2 cells compared to control
due to inhibition of NPM1-ALK activation (Fig. 2c).
ALCL cells are immunophenotypically characterized by
the strong expression of the CD30 marker, a member of
the tumor necrosis factor (TNF) receptor family, which is
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transcriptionally upregulated through the NPM1-ALK-
mediated ERK1/2 and STAT3 pathways15. CD30 activa-
tion contributes to lymphoma cell proliferation through
activated NF-κB and other anti-apoptotic mechanisms.
We analyzed the effect of NPM1-ALK downregulation on
CD30 expression in Karpas-299 and SUDHL-1 cells (Fig.
2d). ALCL cell lines were treated with celastrol and ana-
lyzed for CD30 expression by flow cytometry. The results
showed treatment with celastrol in the SUDHL-1 cell line
exhibited a higher response in the reduction of CD30 in
comparison to Karpas-299 cell line. The differential
response might be due to the variable expression levels of
NPM1-ALK and downstream signaling effector molecules
in these cell lines.
In summary, our results show for the first time that
inhibition of the interaction between CDC37 and HSP90
using celastrol represents a novel therapeutic approach in
ALCL cells expressing the NPM1-ALK fusion gene. These
observations further pave the way to consider CDC37 as a
novel molecular target for the treatment of NPM1-ALK
expressing ALCL cells and warrants developing future
therapeutic intervention strategies.
Fig. 1 Celastrol downregulates NPM1-ALK fusion protein and its signaling: (a) celastrol treatment depletes NPM1-ALK protein levels and inhibits
activation of NPM1-ALK fusion kinase. NPM1-ALK expressing SUDHL-1, Karpas-299, SUP-M2, SR-786, DEL, and Ba/F3-FG-NPM1-ALK cells were treated
with indicated concentrations of celastrol for 24 h. At the end of the treatment period, cell lysates were made, and immunoblot analyses were
performed for total NPM1-ALK and phospho-NPM1-ALK proteins. b Depletion of NPM1-ALK leads to inhibition of downstream survival signaling
cascade. NPM1-ALK expressing ALCL cell lines treated with celastrol and western blot analyses were performed for downstream effector molecules
pSTAT3, pAKT, pERK1/2 along with total proteins. β-actin served as the loading control
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Fig. 2 (See legend on next page.)
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Fig. 2 Celastrol induces apoptosis in ALCL cells: (a) downregulation of NPM1-ALK induces apoptosis. The NPM1-ALK expressing SUDHL-1, Karpas-299,
SUP-M2, SR-786, DEL, Ba/F3-FG-NPM1-ALK cell lines and normal T cells (n= 3) were treated with the indicated concentrations for 48 h. After
treatment, cells were harvested and stained with FITC-annexin V and TO-PRO3, and the percentages of apoptotic cells were determined by flow
cytometry. Columns represent the mean of three independent experiments; bars represent the standard error of the mean (SEM). b Effect of celastrol
on apoptotic proteins: SUDHL-1 and Karpas-299 ALCL cell lines were treated with the indicated concentrations of celastrol for 24 h. At the end of the
treatment, cell lysates were prepared and western blot analyses were performed for cleaved PARP, procaspases 8, 9, Bax, survivin, Bcl2, and c-Myc. β-
Actin served as loading control. c Celastrol inhibits the clonogenic potential of ALCL cells. Karpas-299 and SUP-M2 cells were treated with indicated
concentrations of celastrol for 24 h, washed, mixed with MethoCult medium, and plated. After 8 days of incubation, the number of colonies were
counted. A portion of the full image is enlarged for clear visualization of colonies (Karpas-299). Columns represent the mean of three independent
experiments; bars represent the SEM. d Celastrol downregulates the CD30 surface expression in ALCL cell lines. The cells were treated for 24 h with
indicated concentrations of celastrol and stained with anti-CD30-FITC along with respective isotype control antibodies. The CD30-positive cells were
measured by flow cytometry. Columns represent the mean of three independent experiments; bars represent the SEM
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